Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Operating Margin (2020 - 2025)

Bolt Biotherapeutics' Operating Margin history spans 6 years, with the latest figure at 355.14% for Q3 2025.

  • For Q3 2025, Operating Margin rose 108596.0% year-over-year to 355.14%; the TTM value through Sep 2025 reached 884.39%, down 10826.0%, while the annual FY2024 figure was 949.91%, 1754.0% up from the prior year.
  • Operating Margin for Q3 2025 was 355.14% at Bolt Biotherapeutics, up from 510.53% in the prior quarter.
  • Across five years, Operating Margin topped out at 324.08% in Q1 2024 and bottomed at 5329.72% in Q4 2021.
  • The 5-year median for Operating Margin is 1221.0% (2022), against an average of 1554.02%.
  • The largest annual shift saw Operating Margin soared 383858bps in 2022 before it crashed -72184bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 5329.72% in 2021, then skyrocketed by 72bps to 1491.14% in 2022, then surged by 37bps to 946.19% in 2023, then crashed by -52bps to 1441.1% in 2024, then surged by 75bps to 355.14% in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Operating Margin are 355.14% (Q3 2025), 510.53% (Q2 2025), and 991.41% (Q1 2025).